Volpara Health Technologies (ASX:VHT) - CEO, Dr Ralph Highnam
CEO, Dr Ralph Highnam
Source: Volpara
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Volpara Health Technologies (VHT) has partnered with Ambry Genetics to improve the standard of care for breast cancer patients in the U.S
  • Volpara is a medtech company with a range of breast imaging technologies that improve decision-making and early detection of breast cancer
  • It will utilise its technologies with Ambry’s CARE Program to ensure more patients get access to the right type of care
  • Volpara is up 4.41 per cent and shares are trading for $1.54 each

Volpara Health Technologies (VHT) has partnered with Ambry Genetics to improve the standard of care for breast cancer patients in the United States.

Volpara is a New Zealand-based medtech company with a range of breast imaging technologies and analysis products that improve clinical decision-making and the early detection of breast cancer.

Ambry Genetics is considered a leading clinical genetic testing company that has developed the CARE program. The CARE Program is a precision medicine platform that helps ensure more patients get access to recommended care.

“Our partnership with Ambry will allow us to offer additional value to our customers to ensure the right patients get the right testing at the right time,” Volpara CEO Dr Ralph Highnam said.

“Personalisation of breast cancer screening based on risk is being adopted at a fast pace in the U.S., and Volpara is proud to be playing a major role in that,” he added.

At least one Volpara software product is used in over 27 per cent of women who attend screening each year in the U.S. Customers also utilise Volpara’s VolparaDensity software for automated breast density assessment, along with breast cancer risk assessment modules in Aspen Breast, the company’s newest technology.

These software products help providers make better informed decisions about triaging patients based on risk.

“We are excited about this partnership opportunity and the ability to help give providers confidence and peace-of-mind in elevating the standard of care for their patients,” Ambry Genetics Chief Commercial Officer Tom Schoenherr said.

Volpara is up 4.41 per cent and shares are trading for $1.54 each at market close.

VHT by the numbers
More From The Market Online

PainCheck receives European patent for pain assessment technology

PainCheck®, developer of the world’s first smartphone-based pain assessment and monitoring application, has been granted a…

Bailador invests in Updoc digital healthcare platform

Bailador Technology Investments (ASX:BTI) has announced a $20million investment in Venture Startups International (Updoc).

Cleo Diagnostics reports its ovarian cancer blood tests superior to ultrasound

Nine moths after listing on the ASX, Cleo Diagnostics (ASX:COV) has made its first major biotech breakthrough.